Effect of different doses of nasal salmon calcitonin on bone mass.

Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK, Sørensen OH

Calcified tissue international1 May 1991Cited by 34 (Europe PMC)

PMID2054714DOI10.1007/bf02556148PepBankPUB-02054714

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with a former Colles' fracture, the lumbar spine bone mineral content rate of change was 0.2 gHA per year with 50 IU per day nasal salmon calcitonin, compared with 0.7 gHA per year with placebo.
In plain wordsIn postmenopausal women, lumbar spine bone mineral content changed by 0.2 gHA per year on 50 IU per day sCT, compared with 0.7 on placebo.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedLumbar spine bone mineral content
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU per day · intranasal · 1 yearAs given in this study (human).
Measurements
Bone mineral content change
0.2 gHA per year
50 IU per day
Source sentences
Summary
The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass.
Summary · context
They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray.
Report a problemFND-0205471401
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with a former Colles' fracture, the lumbar spine bone mineral content rate of change was 1.1 gHA per year with 100 IU per day nasal salmon calcitonin, compared with 0.7 gHA per year with placebo.
In plain wordsIn postmenopausal women, lumbar spine bone mineral content changed by 1.1 gHA per year on 100 IU sCT per day, compared with 0.7 on placebo.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine bone mineral content
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU per day · intranasal · 1 yearAs given in this study (human).
Measurements
Bone mineral content change
1.1 gHA per year
100 IU per day
Source sentences
Summary
The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass.
Summary · context
They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray.
Report a problemFND-0205471402
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with a former Colles' fracture, the lumbar spine bone mineral content rate of change was 2.0 gHA per year with 200 IU per day nasal salmon calcitonin, which differed significantly from zero (P less than 0.01), compared with 0.7 gHA per year with placebo.
In plain wordsIn postmenopausal women, lumbar spine bone mineral content rose 2.0 gHA per year on 200 IU sCT per day, significantly different from zero; placebo 0.7.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine bone mineral content
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU per day · intranasal · 1 yearAs given in this study (human).
Measurements
Bone mineral content change
2 gHA per year
200 IU per day
Source sentences
Summary
The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The rate of change in the bone mineral content of the lumbar spine in patients receiving 200 IU of SCT per day differed significantly from zero (P less than 0.01).
Summary · context
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass.
Summary · context
They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray.
Report a problemFND-0205471403
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with a former Colles' fracture, the forearm bone mineral content rate of change was -0.1 AU per year with 50 IU per day nasal salmon calcitonin, compared with -0.4 AU per year with placebo.
In plain wordsIn postmenopausal women, forearm bone mineral content changed by -0.1 AU per year on 50 IU sCT per day, compared with -0.4 on placebo.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedForearm bone mineral content
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU per day · intranasal · 1 yearAs given in this study (human).
Measurements
Bone mineral content change
−0.1 AU per year
50 IU per day
Source sentences
Summary
The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass.
Summary · context
They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray.
Report a problemFND-0205471404
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with a former Colles' fracture, the forearm bone mineral content rate of change was 0.0 AU per year with 100 IU per day nasal salmon calcitonin, compared with -0.4 AU per year with placebo.
In plain wordsIn postmenopausal women, forearm bone mineral content changed by 0.0 AU per year on 100 IU sCT per day, compared with -0.4 on placebo.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedForearm bone mineral content
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU per day · intranasal · 1 yearAs given in this study (human).
Measurements
Bone mineral content change
0 AU per year
100 IU per day
Source sentences
Summary
The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass.
Summary · context
They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray.
Report a problemFND-0205471405
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with a former Colles' fracture, the forearm bone mineral content rate of change was -0.1 AU per year with 200 IU per day nasal salmon calcitonin, compared with -0.4 AU per year with placebo.
In plain wordsIn postmenopausal women, forearm bone mineral content changed by -0.1 AU per year on 200 IU sCT per day, compared with -0.4 on placebo.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedForearm bone mineral content
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU per day · intranasal · 1 yearAs given in this study (human).
Measurements
Bone mineral content change
−0.1 AU per year
200 IU per day
Source sentences
Summary
The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass.
Summary · context
They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray.
Report a problemFND-0205471406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.